Medication info
MANTINI 5mg Tablet (Memantine Hydrochloride)

MANTINI 5mg Tablet (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›5mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202503180 · Approved 2025.12.05

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This medicine is administered orally once daily at the same time each day. If necessary, this medicine may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1~7): Administer 5mg once daily for 7 days. Week 2 (Days 8~14): Administer 10mg once daily for 7 days. Week 3 (Days 15~21): Administer 15mg once daily for 7 days. From Week 4 onward, administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Elderly patients Based on clinical data, the recommended dose for elderly patients aged 65 years and older is 20mg daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg daily according to the standard dose escalation schedule no earlier than 7 days after administration. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medication is used for the treatment of moderate to severe Alzheimer's disease. It may help improve the patient's cognitive function and daily living abilities.

How to take

Adult dose

This medicine is administered orally once daily at the same time each day. If necessary, this medicine may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1~7): Administer 5mg once daily for 7 days. Week 2 (Days 8~14): Administer 10mg once daily for 7 days. Week 3 (Days 15~21): Administer 15mg once daily for 7 days. From Week 4 onward, administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Elderly patients Based on clinical data, the recommended dose for elderly patients aged 65 years and older is 20mg daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg daily according to the standard dose escalation schedule no earlier than 7 days after administration. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). As there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Precautions

This medication should not be administered to patients who are allergic to its components. It should also not be used in patients with severely impaired liver function or significant renal impairment. Caution is advised in patients with epilepsy, those with a history of seizures, or those with a predisposition to seizures. Additionally, concurrent use with NMDA receptor antagonists such as amantadine, ketamine, or dextromethorphan may increase central nervous system side effects, so they should not be used together. In situations or conditions where the acidity of urine may change, careful monitoring of urine status is necessary. Patients who have recently experienced myocardial infarction, heart failure, or uncontrolled hypertension require caution due to insufficient information about the safety of this drug. While taking this medication, symptoms such as dizziness, headache, constipation, drowsiness, and hypertension may occur, and these symptoms are generally mild to moderate. Psychiatric adverse reactions such as confusion, hallucinations, and psychotic symptoms may occur rarely, so caution is needed. This medication may interact with other drugs; therefore, especially when taken with levodopa, dopamine agonists, anticholinergics, barbiturates, antipsychotics, and skeletal muscle relaxants, consultation with a specialist is advised. Women who are pregnant or of childbearing potential should consult a doctor before taking this medication, and breastfeeding is recommended to be discontinued while on this medication. It is advisable not to use this medication in children or adolescents under 18 years of age, as safety and efficacy have not been established. In case of overdose, central nervous system symptoms or gastrointestinal symptoms may appear, and appropriate medical treatment should be sought immediately. This medication may affect the patient's reaction speed, so caution is necessary when driving or operating machinery. Finally, keep this medication out of the reach of children and do not transfer it to other containers.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • confusion
  • hallucinations
  • psychiatric reactions
Show 24 more
  • balance disorder
  • gait abnormalities
  • seizures
  • heart failure
  • venous thrombosis/thromboembolism
  • difficulty breathing
  • vomiting
  • pancreatitis
  • elevated liver function tests
  • hepatitis
  • fatigue
  • nonspecific tiredness
  • weakness
  • diarrhea
  • anxiety
  • aggression
  • stupor
  • unconsciousness
  • double vision
  • restlessness
  • psychosis
  • visual hallucinations
  • convulsions
  • coma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.